• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

With Mammograms and Improved Treatment, How many Breast Cancer Deaths have Been Averted?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Screening mammography
    • Widely available during 1980s
    • Increased use through to early 2000s with peak estimates in 2000
      • Annual mammogram: 25% of women >40 years
      • Biennial: 25%
      • Irregular or none: 64%
  • Different models have been used to determine how much of the decline in breast cancer mortality rates are due to screening vs treatment
  • Hendrick et al. (Cancer, 2019) sought to determine the mortality reduction resulting from the collective effects of mammography and treatment

METHODS:

  • Age-adjusted female breast cancer mortality rate and population data was collected from Surveillance, Epidemiology, and End Results (SEER) database
  • Background mortality rates were created using four different assumptions in the absence of screening mammography and improved treatment
  • Estimated deaths averted was estimated for women aged 40 to 84 years by taking difference between SEER report and background mortality rates for each 5 year age group
  • Extrapolated SEER data were used to estimate deaths averted in 2018

RESULTS:

  • The number of single-year breast cancer deaths averted ranged from
    • 2012: 20,860 to 33,842
    • 2015: 23,703 to 39,415
    • 2018: 27,083 to 45,726
  • Breast cancer mortality reductions ranged from
    • 2012; 38.6% to 50.5%
    • 2015: 41.5% to 54.2%
    • 2018: 45.3% to 58.3%
  • Cumulative breast cancer deaths averted since 1989 ranged from
    • 2012: 237,234 to 370,402
    • 2015: 305,934 to 483,435
    • 2018: 384,046 to 614,484

CONCLUSION:

Learn More – Primary Sources:

Breast cancer deaths averted over 3 decades

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

USPSTF Guidance: When to Use Medication to Reduce Breast Cancer Risk
Mammography Guidelines for Average-Risk Women
A Breast Cancer Diagnosis in the Interval Between Mammograms: Who is at Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site